DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today...
Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering
Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000...
31 juli 2025
Gilde Healthcare’s private equity fonds bundelt Artinis en NIRx tot wereldleider in neuro-imaging
Gilde Healthcare kondigt vandaag de gecombineerde private equity investering aan in Artinis Medical Systems (Nederland) en NIRx Medical Technologies (Duitsland/Verenigde Staten), beiden pioniers op het gebied van functionele Near-Infrared Spectroscopy...
8 juli 2025
Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline
DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today...
5 augustus 2025